logo

Fate Therapeutics, Inc (FATE)



Trade FATE now with
  Date
  Headline
9/20/2018 11:49:42 PM Fate Therapeutics Announces Pricing Of Public Offering Of 9.26 Mln Shares At $13.50/Shr
9/20/2018 4:11:42 PM Fate Therapeutics Announces Proposed Public Offering Of Common Stock
9/19/2018 6:40:19 AM Wedbush Is Raising Fate Therapeutics, Inc (FATE) FY18 Rev. Estimate To 14.1 M From 5.2 M
9/19/2018 6:39:45 AM Wedbush Is Raising Fate Therapeutics, Inc (FATE) FY18 Estimate To -1.01 From -1.17
9/19/2018 6:39:27 AM Wedbush Is Raising Fate Therapeutics, Inc (FATE) Q3 18 Estimate To -0.10 From -0.27
9/19/2018 6:39:04 AM Wedbush Reiterates Fate Therapeutics, Inc (FATE) At Outperform With $19 Price Target
8/7/2018 8:18:29 AM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) FY18 Estimate To -1.17 From -0.99
8/7/2018 8:18:17 AM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q4 18 Estimate To -0.27 From -0.22
8/7/2018 8:18:07 AM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) Q3 18 Estimate To -0.27 From -0.25
8/7/2018 8:17:46 AM Wedbush Reiterates Fate Therapeutics, Inc (FATE) At Outperform With $19 Price Target
5/11/2018 1:52:31 PM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) FY18 Estimate To -0.99 From -0.87
5/11/2018 1:52:15 PM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) Q4 18 Estimate To -0.22 From -0.21
5/11/2018 1:51:54 PM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q3 18 Estimate To -0.25 From -0.24
5/11/2018 1:51:43 PM Wedbush Is Cutting Fate Therapeutics, Inc (FATE) Q2 18 Estimate To -0.26 From -0.25
3/29/2018 2:34:15 PM Wedbush Reiterates Fate Therapeutics, Inc (FATE) At Outperform With $19 Price Target
3/29/2018 8:13:09 AM Fate Therapeutics Announces Initial Clinical Data Of FATE-NK100 For Recurrent Ovarian Cancer
3/19/2018 8:12:06 AM Fate Therapeutics Announces Addl Clinical Data From Phase 1 Stage Of PROTECT Trial Of ProTmune
3/6/2018 7:44:45 AM Wedbush Is Raising Fate Therapeutics, Inc (FATE) FY18 Rev. Estimate To 8.1 M From 4.1 M
3/6/2018 7:43:54 AM Wedbush Is Lowering Fate Therapeutics, Inc (FATE) FY18 Estimate To -0.87 From -0.84